Clinical Cancer Research, Vol 4, Issue 10 2455-2461, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer

C Rancourt, BE Rogers, BA Sosnowski, M Wang, A Piche, GF Pierce, RD Alvarez, GP Siegal, JT Douglas and DT Curiel
Gene Therapy Program, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294, USA.

A number of preclinical and human clinical gene therapy trials using adenoviral vectors have shown that the number of viral particles necessary to give adequate levels of gene transfer can be associated with significant vector-related toxicity. In an effort to reduce the number of adenoviral particles required for a given level of gene transfer, we sought to redirect adenoviral infection via a receptor that is highly expressed on the target cells. By using basic fibroblast growth factor (FGF2) as the targeting ligand, adenovirus-mediated gene transfer to the human ovarian cancer cell line SKOV3.ip1 was significantly enhanced, permitting the transduction of a greater number of target cells to be achieved by a given dose of virus. In a murine model of human ovarian carcinoma, an FGF2-redirected adenoviral vector carrying the gene for herpes simplex virus thymidine kinase (AdCMVHSV-TK) was shown to result in a significant prolongation of survival compared with the same number of particles of unmodified AdCMVHSV-TK. In addition, equivalent survival rates were achieved with a 10-fold lower dose of the FGF2-redirected AdCMVHSV-TK compared with the unmodified vector. To our knowledge, this is the first report demonstrating that strategies to enhance the efficiency of in vivo transduction of adenoviral vectors will be of clinical utility.

This article has been cited by other articles:

				A. Al-Hendy and S. Salama Gene therapy and uterine leiomyoma: a review Hum. Reprod. Update, July 1, 2006; 12(4): 385 - 400. [Abstract] [Full Text] [PDF]

				M. Qin, B. Escuadro, S. Sharma, and R. K. Batra Gene Transfer Mediated by Native versus Fibroblast Growth Factor-Retargeted Adenoviral Vectors into Lung Cancer Cells Am. J. Respir. Cell Mol. Biol., March 1, 2005; 32(3): 211 - 217. [Abstract] [Full Text] [PDF]

				K. Toth, H. Djeha, B. Ying, A. E. Tollefson, M. Kuppuswamy, K. Doronin, P. Krajcsi, K. Lipinski, C. J. Wrighton, and W. S. M. Wold An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling Cancer Res., May 15, 2004; 64(10): 3638 - 3644. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				Y. Kawakami, H. Li, J. T. Lam, V. Krasnykh, D. T. Curiel, and J. L. Blackwell Substitution of the Adenovirus Serotype 5 Knob with a Serotype 3 Knob Enhances Multiple Steps in Virus Replication Cancer Res., March 15, 2003; 63(6): 1262 - 1269. [Abstract] [Full Text] [PDF]

				T. D. de Gruijl, S. A. Luykx-de Bakker, B. W. Tillman, A. J. M. van den Eertwegh, J. Buter, S. M. Lougheed, G. J. van der Bij, A. M. Safer, H. J. Haisma, D. T. Curiel, et al. Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors J. Immunol., November 1, 2002; 169(9): 5322 - 5331. [Abstract] [Full Text] [PDF]

				Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, et al. Adenoviral Gene Therapy for Renal Cancer Requires Retargeting to Alternative Cellular Receptors Cancer Res., August 1, 2002; 62(15): 4273 - 4281. [Abstract] [Full Text] [PDF]

				D. M. Shayakhmetov, Z.-Y. Li, S. Ni, and A. Lieber Targeting of Adenovirus Vectors to Tumor Cells Does Not Enable Efficient Transduction of Breast Cancer Metastases Cancer Res., February 1, 2002; 62(4): 1063 - 1068. [Abstract] [Full Text] [PDF]

				E. A. Kashentseva, T. Seki, D. T. Curiel, and I. P. Dmitriev Adenovirus Targeting to c-erbB-2 Oncoprotein by Single-Chain Antibody Fused to Trimeric Form of Adenovirus Receptor Ectodomain Cancer Res., January 1, 2002; 62(2): 609 - 616. [Abstract] [Full Text] [PDF]

				P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066. [Abstract] [Full Text] [PDF]

				J. Grill, V. W. Van Beusechem, P. Van Der Valk, C. M. F. Dirven, A. Leonhart, D. S. Pherai, H. J. Haisma, H. M. Pinedo, D. T. Curiel, and W. R. Gerritsen Combined Targeting of Adenoviruses to Integrins and Epidermal Growth Factor Receptors Increases Gene Transfer into Primary Glioma Cells and Spheroids Clin. Cancer Res., March 1, 2001; 7(3): 641 - 650. [Abstract] [Full Text]

				J. T. Douglas, M. Kim, L. A. Sumerel, D. E. Carey, and D. T. Curiel Efficient Oncolysis by a Replicating Adenovirus (Ad) in Vivo Is Critically Dependent on Tumor Expression of Primary Ad Receptors Cancer Res., February 1, 2001; 61(3): 813 - 817. [Abstract] [Full Text]

				V. Krasnykh, I. Dmitriev, J.-G. Navarro, N. Belousova, E. Kashentseva, J. Xiang, J. T. Douglas, and D. T. Curiel Advanced Generation Adenoviral Vectors Possess Augmented Gene Transfer Efficiency Based upon Coxsackie Adenovirus Receptor-independent Cellular Entry Capacity Cancer Res., December 1, 2000; 60(24): 6784 - 6787. [Abstract] [Full Text]

				K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. N. Dinney Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor Clin. Cancer Res., November 1, 2000; 6(11): 4422 - 4431. [Abstract] [Full Text] [PDF]

				B. W. Tillman, T. L. Hayes, T. D. deGruijl, J. T. Douglas, and D. T. Curiel Adenoviral Vectors Targeted to CD40 Enhance the Efficacy of Dendritic Cell-based Vaccination against Human Papillomavirus 16-induced Tumor Cells in a Murine Model Cancer Res., October 1, 2000; 60(19): 5456 - 5463. [Abstract] [Full Text]

				K. F. Roby, C. C. Taylor, J. P. Sweetwood, Y. Cheng, J. L. Pace, O. Tawfik, D. L. Persons, P. G. Smith, and P. F. Terranova Development of a syngeneic mouse model for events related to ovarian cancer Carcinogenesis, April 1, 2000; 21(4): 585 - 591. [Abstract] [Full Text] [PDF]

				D. J. Von Seggern, S. Huang, S. K. Fleck, S. C. Stevenson, and G. R. Nemerow Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells J. Virol., January 1, 2000; 74(1): 354 - 362. [Abstract] [Full Text]

				J. DOUKAS, D. K. HOGANSON, M. ONG, W. YING, D. L. LACEY, A. BAIRD, G. F. PIERCE, and B. A. SOSNOWSKI Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways FASEB J, August 1, 1999; 13(11): 1459 - 1466. [Abstract] [Full Text]

				D.-l. Gu, A. M. Gonzalez, M. A. Printz, J. Doukas, W. Ying, M. D'Andrea, D. K. Hoganson, D. T. Curiel, J. T. Douglas, B. A. Sosnowski, et al. Fibroblast Growth Factor 2 Retargeted Adenovirus Has Redirected Cellular Tropism: Evidence for Reduced Toxicity and Enhanced AntitumorActivity in Mice Cancer Res., June 1, 1999; 59(11): 2608 - 2614. [Abstract] [Full Text] [PDF]

				B. E. Rogers, S. F. McLean, R. L. Kirkman, D. Della Manna, S. J. Bright, C. C. Olsen, A. D. Myracle, M. S. Mayo, D. T. Curiel, and D. J. Buchsbaum In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector Clin. Cancer Res., February 1, 1999; 5(2): 383 - 393. [Abstract] [Full Text] [PDF]